MIRM

Mirum Pharmaceuticals

• TipRanks·03/30 10:35

  Mirum Therapeutics: Favorable Risk/Reward Ahead of Key 2Q26 VISTAS Readout for Volixibat in PSC

• Dow Jones·03/27 15:37

  Mirum Pharmaceuticals Is Maintained at Buy by TD Cowen

• Benzinga·03/27 15:29

  TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $125

• TipRanks·03/27 12:33

  Mirum Pharmaceuticals price target raised to $125 from $117 at TD Cowen

• TipRanks·03/27 10:20

  Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Mirum Pharmaceuticals (MIRM) and NovoCure (NVCR)

• Dow Jones·03/23 11:10

  Mirum Pharmaceuticals Price Target Maintained With a $130.00/Share by HC Wainwright & Co.

• Benzinga·03/23 11:00

  HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $130 Price Target

• TipRanks·03/23 10:16

  Buy Rating on Mirum Pharmaceuticals Driven by Volixibat’s Differentiated IBAT Profile, Favorable PBC Market Dynamics, and Upside from PSC Expansion

• Reuters·03/17 23:30

  Mirum Pharmaceuticals Director Saira Ramasastry Disposes of USD 181,520 in Common Shares

• TipRanks·03/16 12:06

  Mirum Pharmaceuticals completes enrollment in EXPAND study

• Reuters·03/16 12:01

  Mirum Pharmaceuticals completes enrollment in Phase 3 EXPAND trial of LIVMARLI for cholestatic pruritus in rare liver diseases

• Reuters·03/16 12:00

  MIRUM PHARMACEUTICALS INC - TOPLINE DATA FROM EXPAND STUDY EXPECTED IN Q4 2026

• Reuters·03/12 21:30

  Mirum Pharmaceuticals reports inducement grants of 5,400 stock options and 6,800 RSUs under its 2020 plan

• Reuters·03/12 21:30

  MIRUM PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)